Slingshot members are tracking this event:

AbbVie Receives EMA Orphan Drug Designation for Investigational Compound Venetoclax for the Treatment of Acute Myeloid Leukemia (AML)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
ABBV Community voting in process

Additional Information

Additional Relevant Details European Medicines Agency (EMA) has granted Orphan Drug Designation to venetoclax, an investigational, oral B-cell lymphoma-2 (BCL-2) inhibitor, for the treatment of acute myeloid leukemia (AML). AML can be a rapidly progressing cancer of the blood and bone marrow and is the most common type of acute leukemia in adults. Venetoclax is being developed by AbbVie in partnership with Genentech and Roche.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 26, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Ema, Orphan Drug Designation, Venetoclax, Aml, Acute Myeloid Leukemia, Myeloblast, Healthy Blood Cells, Chronic Lymphocytic Leukemia